Ras and Rap1: A tale of two GTPases

Vigil, 2010, Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?, Nat. Rev. Cancer, 10, 842, 10.1038/nrc2960 Rojas, 2011, Mammalian son of sevenless Guanine nucleotide exchange factors: old concepts and new perspectives, Genes Cancer, 2, 298, 10.1177/1947601911408078 Buday, 2008, Many faces of Ras activation, Biochim. Biophys. Acta, 1786, 178 Brock, 2016, How to target activated Ras proteins: direct inhibition vs. Induced mislocalization, Mini Rev. Med. Chem., 16, 358, 10.2174/1389557515666151001154002 Wilson, 2016, Recent advances in cancer drug discovery targeting, RAS Drug. Discov. Today, 21, 1915, 10.1016/j.drudis.2016.08.002 Whitwam, 2007, Differential oncogenic potential of activated RAS isoforms in melanocytes, Oncogene, 26, 4563, 10.1038/sj.onc.1210239 Prior, 2012, Ras trafficking, localization and compartmentalized signalling, Semin. Cell Dev. Biol., 23, 145, 10.1016/j.semcdb.2011.09.002 Nussinov, 2015, Principles of K-Ras effector organization and the role of oncogenic K-Ras in cancer initiation through G1 cell cycle deregulation, Expert Rev. Proteom., 12, 669, 10.1586/14789450.2015.1100079 Hobbs, 2016, RAS isoforms and mutations in cancer at a glance, J. Cell Sci., 129, 1287, 10.1242/jcs.182873 Castellano, 2011, Functional specificity of ras isoforms: so similar but so different, Genes Cancer, 2, 216, 10.1177/1947601911408081 Fotiadou, 2007, Wild-type NRas and KRas perform distinct functions during transformation, Mol. Cell. Biol., 27, 6742, 10.1128/MCB.00234-07 Wolfman, 2001, Ras isoform-specific signaling: location, location, location, Sci. STKE, 2001, pe2, 10.1126/stke.2001.96.pe2 Omerovic, 2008, Ras isoform abundance and signalling in human cancer cell lines, Oncogene, 27, 2754, 10.1038/sj.onc.1210925 Miller, 2011, RAS mutations and oncogenesis: not all RAS mutations are created equally, Front. Genet., 2, 100 Prior, 2001, GTP-dependent segregation of H-ras from lipid rafts is required for biological activity, Nat. Cell Biol., 3, 368, 10.1038/35070050 Hancock, 2003, Ras proteins: different signals from different locations, Nat. Rev. Mol. Cell Biol., 4, 373, 10.1038/nrm1105 ten Klooster, 2007, Targeting and localized signalling by small GTPases, Biol. Cell, 99, 1, 10.1042/BC20060071 Prior, 2003, Direct visualization of Ras proteins in spatially distinct cell surface microdomains, J. Cell Biol., 160, 165, 10.1083/jcb.200209091 Chiu, 2002, Ras signalling on the endoplasmic reticulum and the golgi, Nat. Cell Biol., 4, 343, 10.1038/ncb783 Baker, 2013, Differences in the regulation of K-Ras and H-Ras isoforms by monoubiquitination, J. Biol. Chem., 288, 36856, 10.1074/jbc.C113.525691 Arozarena, 2004, Activation of H-Ras in the endoplasmic reticulum by the RasGRF family guanine nucleotide exchange factors, Molecular, 24, 1516 Hamilton, 1998, Ha-ras and N-ras regulate MAPK activity by distinct mechanisms in vivo, Oncogene, 16, 1417, 10.1038/sj.onc.1201653 Hahn, 1999, Creation of human tumour cells with defined genetic elements, Nature, 400, 464, 10.1038/22780 Zhao, 2014, Targeting oncogenic drivers, Prog. Tumor Res., 41, 1, 10.1159/000355895 Chin, 1999, Essential role for oncogenic Ras in tumour maintenance, Nature, 400, 468, 10.1038/22788 Stephen, 2014, Dragging ras back in the ring, Cancer cell, 25, 272, 10.1016/j.ccr.2014.02.017 Taparowsky, 1982, Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change, Nature, 300, 762, 10.1038/300762a0 Santos, 1982, T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes, Nature, 298, 343, 10.1038/298343a0 Parada, 1982, Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene, Nature, 297, 474, 10.1038/297474a0 Der, 1982, Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses, Proc. Natl. Acad. Sci. U. S. A., 79, 3637, 10.1073/pnas.79.11.3637 Siegel, 2016, Cancer statistics, 2016, CA Cancer J. Clin., 66, 7, 10.3322/caac.21332 Baines, 2011, Inhibition of Ras for cancer treatment: the search continues, Future Med. Chem., 3, 1787, 10.4155/fmc.11.121 Prior, 2012, A comprehensive survey of Ras mutations in cancer, Cancer Res., 72, 2457, 10.1158/0008-5472.CAN-11-2612 Rodenhuis, 1992, Ras and human tumors, Semin. Cancer Biol., 3, 241 Fearon, 2011, Molecular genetics of colorectal cancer, Annu. Rev. Pathol., 6, 479, 10.1146/annurev-pathol-011110-130235 Collins, 2012, Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice, J. Clin. Invest., 122, 639, 10.1172/JCI59227 Ryan, 2014, Pancreatic adenocarcinoma, N. Engl. J. Med., 371, 1039, 10.1056/NEJMra1404198 Tong, 2014, Characterization of rare transforming KRAS mutations in sporadic colorectal cancer, Cancer Biol. Ther., 15, 768, 10.4161/cbt.28550 Cox, 2015, Targeting RAS membrane association: Back to the future for anti-RAS drug discovery?, Clin. Cancer Res., 21, 1819, 10.1158/1078-0432.CCR-14-3214 Cox, 2014, Drugging the undruggable RAS: mission possible?, Nat. Rev. Drug Discov., 13, 828, 10.1038/nrd4389 Bournet, 2016, KRAS G12D mutation subtype is a prognostic factor for advanced pancreatic adenocarcinoma, Clin. Transl. Gastroenterol., 7, e157, 10.1038/ctg.2016.18 Westover, 2016, Progress on covalent inhibition of KRAS(G12C), Cancer Discov., 6, 233, 10.1158/2159-8290.CD-16-0092 Lu, 2016, The structural basis of oncogenic mutations G12, G13 and Q61 in small GTPase K-Ras4B, Sci. Rep., 6, 21949, 10.1038/srep21949 Mattingly, 2013, Activated Ras as a therapeutic target: constraints on directly targeting Ras isoforms and wild-type versus mutated proteins, ISRN Oncol., 2013 Lim, 2008, Tumour maintenance is mediated by eNOS, Nature, 452, 646, 10.1038/nature06778 Bentley, 2013, A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation, Biochem. J., 452, 313, 10.1042/BJ20121578 Mattingly, 2006, The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines, J. Pharmacol. Exp. Ther., 316, 456, 10.1124/jpet.105.091454 Philpott, 2017, The NF1 somatic mutational landscape in sporadic human cancers, Hum. Genomics, 11, 13, 10.1186/s40246-017-0109-3 Eckert, 2004, Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis, Cancer Res., 64, 4585, 10.1158/0008-5472.CAN-04-0396 Wallace, 2012, Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver, Genetics, 192, 385, 10.1534/genetics.112.142802 Kim, 2015, Activation of KRAS promotes the mesenchymal features of basal-type breast cancer, Exp. Mol. Med., 47, e137, 10.1038/emm.2014.99 Wright, 2015, Ras signaling is a key determinant for metastatic dissemination and poor survival of luminal breast cancer patients, Cancer Res., 75, 4960, 10.1158/0008-5472.CAN-14-2992 Bill, 2015, The relevance of EMT in breast cancer metastasis: correlation or causality?, FEBS Lett., 589, 1577, 10.1016/j.febslet.2015.05.002 Sanchez-Tillo, 2012, EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness cellular and molecular life sciences, CMLS, 69, 3429, 10.1007/s00018-012-1122-2 De Craene, 2013, Regulatory networks defining EMT during cancer initiation and progression, Nat. Rev. Cancer, 13, 97, 10.1038/nrc3447 Sciacovelli, 2017, Metabolic reprogramming and epithelial-to-mesenchymal transition in cancer, FEBS J., 284, 3132, 10.1111/febs.14090 Vander Heiden, 2009, Understanding the Warburg effect: the metabolic requirements of cell proliferation, Science, 324, 1029, 10.1126/science.1160809 White, 2013, Exploiting the bad eating habits of Ras-driven cancers, Gene Dev., 27, 2065, 10.1101/gad.228122.113 Stine, 2013, Stress eating and tuning out: cancer cells re-wire metabolism to counter stress, Crit. Rev. Biochem. Mol. Biol., 48, 609, 10.3109/10409238.2013.844093 Lunt, 2011, Aerobic glycolysis: meeting the metabolic requirements of cell proliferation, Annu. Rev. Cell Dev. Biol., 27, 441, 10.1146/annurev-cellbio-092910-154237 Onodera, 2014, Increased sugar uptake promotes oncogenesis via EPAC/RAP1 and O-GlcNAc pathways, J. Clin. Invest., 124, 367, 10.1172/JCI63146 Bissell, 2011, Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression, Nat. Med., 17, 320, 10.1038/nm.2328 Shiraishi, 2015, Glycolysis is the primary bioenergetic pathway for cell motility and cytoskeletal remodeling in human prostate and breast cancer cells, Oncotarget, 6, 130, 10.18632/oncotarget.2766 Shaul, 2014, Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition, Cell, 158, 1094, 10.1016/j.cell.2014.07.032 Ying, 2012, Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism, Cell, 149, 656, 10.1016/j.cell.2012.01.058 Son, 2013, Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway, Nature, 496, 101, 10.1038/nature12040 Yun, 2009, Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells, Science, 325, 1555, 10.1126/science.1174229 Peeters, 2017, Fructose-1,6-bisphosphate couples glycolytic flux to activation of Ras, Nat. Commun., 8, 922, 10.1038/s41467-017-01019-z Dong, 2013, Loss of FBP1 by snail-mediated repression provides metabolic advantages in basal-like breast cancer, Cancer Cell, 23, 316, 10.1016/j.ccr.2013.01.022 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Macara, 1991, The ras superfamily of molecular switches, Cell Signal, 3, 179, 10.1016/0898-6568(91)90043-T Scheffzek, 1997, The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants, Science, 277, 333, 10.1126/science.277.5324.333 Ledford, 2015, Cancer: the Ras renaissance, Nature, 520, 278, 10.1038/520278a John, 1993, Kinetic and structural analysis of the Mg(2+)-binding site of the guanine nucleotide-binding protein p21H-ras, J. Biol. Chem., 268, 923, 10.1016/S0021-9258(18)54022-9 Goekjian, 1999, Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors, and agents in development, Curr. Med. Chem., 6, 877, 10.2174/092986730609220401153113 Arnst, 2017, Discovery and characterization of small molecule Rac1 inhibitors, Oncotarget, 8, 34586, 10.18632/oncotarget.16656 Ostrem, 2013, K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions, Nature, 503, 548, 10.1038/nature12796 Lito, 2016, Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism, Science, 351, 604, 10.1126/science.aad6204 Patricelli, 2016, Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive State, Cancer Discov., 6, 316, 10.1158/2159-8290.CD-15-1105 Shipman, 2016, Signalling: putting the brakes on KRAS-G12C nucleotide cycling, Nat. Rev. Cancer, 16, 127, 10.1038/nrc.2016.13 Sautier, 2016, Latest advances towards Ras inhibition: a medicinal chemistry perspective, Angew. Chem. Int. Ed. Engl., 55, 15982, 10.1002/anie.201608270 Welsch, 2017, Multivalent small-molecule Pan-RAS Inhibitors, Cell, 168, 878, 10.1016/j.cell.2017.02.006 Maurer, 2012, Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity, Proc. Natl. Acad. Sci. U. S. A., 109, 5299, 10.1073/pnas.1116510109 Evelyn, 2014, Rational design of small molecule inhibitors targeting the Ras GEF, SOS1, Chem. Biol., 21, 1618, 10.1016/j.chembiol.2014.09.018 Zimmermann, 2013, Small molecule inhibition of the KRAS-PDEdelta interaction impairs oncogenic KRAS signalling, Nature, 497, 638, 10.1038/nature12205 Schopel, 2013, Bisphenol a binds to Ras proteins and competes with guanine nucleotide exchange: implications for GTPase-selective antagonists, J. Med. Chem., 56, 9664, 10.1021/jm401291q Patgiri, 2011, An orthosteric inhibitor of the Ras-Sos interaction, Nat. Chem. Biol., 7, 585, 10.1038/nchembio.612 Hocker, 2013, Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function, Proc. Natl. Acad. Sci. U. S. A., 110, 10201, 10.1073/pnas.1300016110 Evelyn, 2015, Combined rational design and a high throughput screening platform for identifying chemical inhibitors of a Ras-activating enzyme, J. Biol. Chem., 290, 12879, 10.1074/jbc.M114.634493 Shima, 2013, In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction, Proc. Natl. Acad. Sci. U. S. A., 110, 8182, 10.1073/pnas.1217730110 Athuluri-Divakar, 2016, A small molecule RAS-mimetic disrupts RAS association with effector proteins to block signaling, Cell, 165, 643, 10.1016/j.cell.2016.03.045 Upadhyaya, 2015, Inhibition of Ras signaling by blocking Ras-effector interactions with cyclic peptides, Angew. Chem. Int. Ed. Engl., 54, 7602, 10.1002/anie.201502763 Garcia-Manero, 2016, Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial, Lancet Oncol., 17, 496, 10.1016/S1470-2045(16)00009-7 Gumireddy, 2005, ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent, Cancer cell, 7, 275, 10.1016/j.ccr.2005.02.009 Lu, 2015, In vitro antitumor mechanism of (E)-N-(2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyridin-3-yl)methane sulfonamide, Mol. Pharmacol., 87, 18, 10.1124/mol.114.093245 Jost, 2017, Combined CRISPRi/a-based chemical genetic screens reveal that Rigosertib is a microtubule-destabilizing Agent, Mol. Cell, 68, 210, 10.1016/j.molcel.2017.09.012 Ritt, 2016, Inhibition of Ras/Raf/MEK/ERK pathway signaling by a stress-induced phospho-regulatory circuit, Mol. Cell, 64, 875, 10.1016/j.molcel.2016.10.029 Feramisco, 1985, Transient reversion of ras oncogene-induced cell transformation by antibodies specific for amino acid 12 of ras protein, Nature, 314, 639, 10.1038/314639a0 Clark, 1985, Antibodies specific for amino acid 12 of the ras oncogene product inhibit GTP binding, Proc. Natl. Acad. Sci. U. S. A., 82, 5280, 10.1073/pnas.82.16.5280 Pei, 2017, Targeting Ras with macromolecules, Cold Spring Harb. Perspect. Med. Cochet, 1998, Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression, Cancer Res., 58, 1170 Tanaka, 2003, Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation, EMBO J., 22, 1025, 10.1093/emboj/cdg106 Tanaka, 2010, Interfering with RAS-effector protein interactions prevent RAS-dependent tumour initiation and causes stop-start control of cancer growth, Oncogene, 29, 6064, 10.1038/onc.2010.346 Shin, 2017, Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration, Nat. Commun., 8, 15090, 10.1038/ncomms15090 Willumsen, 1984, The p21 ras C-terminus is required for transformation and membrane association, Nature, 310, 583, 10.1038/310583a0 Jackson, 1990, Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation, Proc. Natl. Acad. Sci. U. S. A., 87, 3042, 10.1073/pnas.87.8.3042 Kim, 1990, Prenylation of mammalian Ras protein in Xenopus oocytes, Mol. Cell. Biol., 10, 5945, 10.1128/MCB.10.11.5945 Gibbs, 1994, Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic, Cell, 77, 175, 10.1016/0092-8674(94)90308-5 Nagasu, 1995, Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956, Cancer Res., 55, 5310 Van Cutsem, 2004, Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer, J. Clin. Oncol., 22, 1430, 10.1200/JCO.2004.10.112 Rao, 2004, Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer, J. Clin. Oncol., 22, 3950, 10.1200/JCO.2004.10.037 Zhang, 1997, Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I, J. Biol. Chem., 272, 10232, 10.1074/jbc.272.15.10232 Whyte, 1997, K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors, J. Biol. Chem., 272, 14459, 10.1074/jbc.272.22.14459 Rowell, 1997, Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo, J. Biol. Chem., 272, 14093, 10.1074/jbc.272.22.14093 Wojtkowiak, 2008, Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin, J. Pharmacol. Exp. Ther., 326, 1, 10.1124/jpet.107.135830 Mattingly, 2002, Potent suppression of proliferation of a10 vascular smooth muscle cells by combined treatment with lovastatin and 3-allylfarnesol, an inhibitor of protein farnesyltransferase, J. Pharmacol. Exp. Ther., 303, 74, 10.1124/jpet.102.036061 Wojtkowiak, 2009, Working together: Farnesyl transferase inhibitors and statins block protein prenylation, Mol. Cell. Pharmacol., 1, 1, 10.4255/mcpharmacol.09.01 Clark, 2007, Synthesis, biochemical, and cellular evaluation of farnesyl monophosphate prodrugs as farnesyltransferase inhibitors, J. Med. Chem., 50, 3274, 10.1021/jm0701829 Sane, 2010, A novel geranylgeranyl transferase inhibitor in combination with lovastatin inhibits proliferation and induces autophagy in STS-26T MPNST cells, J. Pharmacol. Exp. Ther., 333, 23, 10.1124/jpet.109.160192 Wojtkowiak, 2011, Aborted autophagy and nonapoptotic death induced by farnesyl transferase inhibitor and lovastatin, J. Pharmacol. Exp. Ther., 337, 65, 10.1124/jpet.110.174573 Novotny, 2017, Farnesyltransferase-Mediated delivery of a covalent inhibitor overcomes alternative prenylation to mislocalize K-Ras, ACS Chem. Biol., 12, 1956, 10.1021/acschembio.7b00374 Lee, 2016, Farnesyl transferase inhibitor FTI-277 inhibits breast cell invasion and migration by blocking H-Ras activation, Oncol. Lett., 12, 2222, 10.3892/ol.2016.4837 Liu, 1998, Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice, Cancer Res., 58, 4947 Kohl, 1995, Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice, Nat. Med., 1, 792, 10.1038/nm0895-792 Kelemen, 2012, RAS mutations in therapy-related acute myeloid leukemia after successful treatment of acute promyelocytic leukemia, Leuk Lymphoma, 53, 999, 10.3109/10428194.2011.634047 Gong, 2017, Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience, Oncotarget, 8, 42198, 10.18632/oncotarget.15030 Kogita, 2015, Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis, Biochem. Biophys. Res. Commun., 458, 52, 10.1016/j.bbrc.2015.01.064 Kaur, 2012, RNA-Seq of human breast ductal carcinoma in situ models reveals aldehyde dehydrogenase isoform 5A1 as a novel potential target, PloS One, 7, e50249, 10.1371/journal.pone.0050249 Kaur, 2013, Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ, Expert Rev. Mol. Diagn., 13, 151, 10.1586/erm.13.4 Szentkuti, 2015, Correlations between prognosis and regional biomarker profiles in head and neck squamous cell carcinomas, Pathol. Oncol. Res., 21, 643, 10.1007/s12253-014-9869-4 Vermorken, 2008, Platinum-based chemotherapy plus cetuximab in head and neck cancer, N. Engl. J. Med., 359, 1116, 10.1056/NEJMoa0802656 Kamangar, 2006, Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world, J. Clin. Oncol., 24, 2137, 10.1200/JCO.2005.05.2308 Morgillo, 2006, Lonafarnib in cancer therapy, Expert Opin. Investig. Drugs, 15, 709, 10.1517/13543784.15.6.709 Widemann, 2014, Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas, Neuro Oncol., 16, 707, 10.1093/neuonc/nou004 Manabe, 2000, Regulation of long-term potentiation by H-Ras through NMDA receptor phosphorylation, J. Neurosci., 20, 2504, 10.1523/JNEUROSCI.20-07-02504.2000 Gartner, 2004, Enhanced Ras activity in pyramidal neurons induces cellular hypertrophy and changes in afferent and intrinsic connectivity in synRas mice, Int. J. Dev. Neurosci., 22, 165, 10.1016/j.ijdevneu.2004.02.001 Yang, 2006, The Ras-GRF1 exchange factor coordinates activation of H-Ras and Rac1 to control neuronal morphology, Molecular, 17, 2177 Yang, 2003, Phosphorylation of the Ras-GRF1 exchange factor at Ser916/898 reveals activation of Ras signaling in the cerebral cortex, J. Biol. Chem., 278, 13278, 10.1074/jbc.M209805200 Kushner, 2005, Modulation of presynaptic plasticity and learning by the H-ras/extracellular signal-regulated kinase/synapsin I signaling pathway, J. Neurosci., 25, 9721, 10.1523/JNEUROSCI.2836-05.2005 Bompaire, 2017, Chemotherapy-related cognitive impairment or << chemobrain >>: concept and state of art, Geriatr. Psychol. Neuropsychiatr. Vieil., 15, 89 Cox, 2014, Drugging the undruggable RAS: Mission possible?, Nat. Rev. Drug Discov., 13, 828, 10.1038/nrd4389 Ryan, 2015, Targeting RAS-mutant cancers: is ERK the key?, Trends Cancer, 1, 183, 10.1016/j.trecan.2015.10.001 Lim, 2005, Activation of RalA is critical for Ras-induced tumorigenesis of human cells, Cancer Cell, 7, 533, 10.1016/j.ccr.2005.04.030 Castellano, 2011, RAS interaction with PI3K: more than just another effector pathway, Genes Cancer, 2, 261, 10.1177/1947601911408079 Ihle, 2012, Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome, J. Natl. Cancer Inst., 104, 228, 10.1093/jnci/djr523 Alagesan, 2015, Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer, Clin. Cancer Res., 21, 396, 10.1158/1078-0432.CCR-14-1591 White, 1995, Multiple Ras functions can contribute to mammalian cell transformation, Cell, 80, 533, 10.1016/0092-8674(95)90507-3 Khosravi-Far, 1996, Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation, Molecular, 16, 3923 Khosravi-Far, 1995, Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation, Mol. Cell. Biol., 15, 6443, 10.1128/MCB.15.11.6443 Wright, 2013, Trametinib: first global approval, Drugs, 73, 1245, 10.1007/s40265-013-0096-1 Ascierto, 2016, Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial, Lancet Oncol., 17, 1248, 10.1016/S1470-2045(16)30122-X Ascierto, 2013, MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study, Lancet Oncol., 14, 249, 10.1016/S1470-2045(13)70024-X Montero-Conde, 2013, Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in braf-mutant thyroid carcinomas, Cancer Discov., 3, 520, 10.1158/2159-8290.CD-12-0531 Turke, 2012, MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB, Recept. Cancer Res., 72, 3228, 10.1158/0008-5472.CAN-11-3747 Posch, 2013, Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo, Proc. Natl. Acad. Sci. U. S. A., 110, 4015, 10.1073/pnas.1216013110 Furman, 2014, Idelalisib and rituximab in relapsed chronic lymphocytic leukemia, N. Engl. J. Med., 370, 997, 10.1056/NEJMoa1315226 Anderson, 1997, Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin’s B-cell lymphoma, Biochem. Soc. Trans., 25, 705, 10.1042/bst0250705 Chiorazzi, 2005, Chronic lymphocytic leukemia, N. Engl. J. Med., 352, 804, 10.1056/NEJMra041720 Bernal, 2001, Survival of leukemic B cells promoted by engagement of the antigen receptor, Blood, 98, 3050, 10.1182/blood.V98.10.3050 Chen, 2002, Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia, Blood, 100, 4609, 10.1182/blood-2002-06-1683 Herishanu, 2011, The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia, Blood, 117, 563, 10.1182/blood-2010-05-284984 Okkenhaug, 2003, PI3K in lymphocyte development, differentiation and activation, Nat. Rev. Immunol., 3, 317, 10.1038/nri1056 Dreyling, 2017, Phosphatidylinositol 3-Kinase inhibition by Copanlisib in relapsed or refractory indolent lymphoma, J. Clin. Oncol., 35, 3898, 10.1200/JCO.2017.75.4648 Greenwell, 2017, PI3K inhibitors: understanding toxicity mechanisms and management, Oncology (Williston Park), 31, 821 Caron, 2003, Cellular functions of the Rap1 GTP-binding protein: a pattern emerges, J. Cell Sci., 116, 435, 10.1242/jcs.00238 Kitayama, 1989, A ras-related gene with transformation suppressor activity, Cell, 56, 77, 10.1016/0092-8674(89)90985-9 Bos, 1998, All in the family? New insights and questions regarding interconnectivity of Ras, Rap1 and Ral, EMBO J., 17, 6776, 10.1093/emboj/17.23.6776 Cook, 1993, RapV12 antagonizes Ras-dependent activation of ERK1 and ERK2 by LPA and EGF in Rat-1 fibroblasts, EMBO J., 12, 3475, 10.1002/j.1460-2075.1993.tb06022.x Hu, 1997, Coassociation of Rap1A and Ha-Ras with Raf-1 N-terminal region interferes with ras-dependent activation of Raf-1, J. Biol. Chem., 272, 11702, 10.1074/jbc.272.18.11702 Raaijmakers, 2009, Specificity in Ras and Rap signaling, J. Biol. Chem., 284, 10995, 10.1074/jbc.R800061200 Bos, 2001, Rap1 signalling: adhering to new models, Nat. Rev. Mol. Cell Biol., 2, 369, 10.1038/35073073 Wang, 2006, Rap-GEF signaling controls stem cell anchoring to their niche through regulating DE-cadherin-mediated cell adhesion in the Drosophila testis, Dev. Cell, 10, 117, 10.1016/j.devcel.2005.11.004 Knox, 2002, Rap1 GTPase regulation of adherens junction positioning and cell adhesion, Science, 295, 1285, 10.1126/science.1067549 Fukuhara, 2005, Cyclic AMP potentiates vascular endothelial cadherin-mediated cell-cell contact to enhance endothelial barrier function through an Epac-Rap1 signaling pathway, Molecular, 25, 136 Cullere, 2005, Regulation of vascular endothelial barrier function by Epac, a cAMP-activated exchange factor for Rap GTPase, Blood, 105, 1950, 10.1182/blood-2004-05-1987 Bos, 2005, Linking Rap to cell adhesion, Curr. Opin. Cell Biol., 17, 123, 10.1016/j.ceb.2005.02.009 Schwamborn, 2004, The sequential activity of the GTPases Rap1B and Cdc42 determines neuronal polarity, Nat. Neurosci., 7, 923, 10.1038/nn1295 Lafuente, 2004, RIAM, an Ena/VASP and profilin ligand, interacts with Rap1-GTP and mediates Rap1-induced adhesion, Dev. Cell, 7, 585, 10.1016/j.devcel.2004.07.021 Jeon, 2007, Rap1 controls cell adhesion and cell motility through the regulation of myosin II, J. Cell Biol., 176, 1021, 10.1083/jcb.200607072 Gerard, 2007, The par polarity complex regulates Rap1- and chemokine-induced T cell polarization, J. Cell Biol., 176, 863, 10.1083/jcb.200608161 Arthur, 2004, Rap1 promotes cell spreading by localizing Rac guanine nucleotide exchange factors, J. Cell Biol., 167, 111, 10.1083/jcb.200404068 Itoh, 2007, Rap1 integrates tissue polarity, lumen formation, and tumorigenic potential in human breast epithelial cells, Cancer Res., 67, 4759, 10.1158/0008-5472.CAN-06-4246 Retta, 2006, Rap1: a turnabout for the crosstalk between cadherins and integrins, Eur. J. Cell Biol., 85, 283, 10.1016/j.ejcb.2005.09.007 Wiseman, 2002, Stromal effects on mammary gland development and breast cancer, Science, 296, 1046, 10.1126/science.1067431 Lakshmikanthan, 2011, Rap1 promotes VEGFR2 activation and angiogenesis by a mechanism involving integrin alphavbeta(3), Blood, 118, 2015, 10.1182/blood-2011-04-349282 Katagiri, 2003, RAPL, a Rap1-binding molecule that mediates Rap1-induced adhesion through spatial regulation of LFA-1, Nat. Immunol., 4, 741, 10.1038/ni950 Bos, 2003, The role of Rap1 in integrin-mediated cell adhesion, Biochem. Soc. Trans., 31, 83, 10.1042/bst0310083 Enserink, 2004, The cAMP-Epac-Rap1 pathway regulates cell spreading and cell adhesion to laminin-5 through the alpha3beta1 integrin but not the alpha6beta4 integrin, J. Biol. Chem., 279, 44889, 10.1074/jbc.M404599200 Katagiri, 2000, Rap1 is a potent activation signal for leukocyte function-associated antigen 1 distinct from protein kinase C and phosphatidylinositol-3-OH kinase, Mol. Cell. Biol., 20, 1956, 10.1128/MCB.20.6.1956-1969.2000 Reedquist, 2000, The small GTPase, Rap1, mediates CD31-induced integrin adhesion, J. Cell Biol., 148, 1151, 10.1083/jcb.148.6.1151 Sebzda, 2002, Rap1A positively regulates T cells via integrin activation rather than inhibiting lymphocyte signaling, Nat. Immunol., 3, 251, 10.1038/ni765 Suga, 2001, CD98 induces LFA-1-mediated cell adhesion in lymphoid cells via activation of Rap1, FEBS Lett., 489, 249, 10.1016/S0014-5793(00)02222-5 Katagiri, 2002, Rap1 functions as a key regulator of T-cell and antigen-presenting cell interactions and modulates T-cell responses, Mol. Cell. Biol., 22, 1001, 10.1128/MCB.22.4.1001-1015.2002 Stork, 2003, Does Rap1 deserve a bad Rap?, Trends Biochem. Sci, 28, 267, 10.1016/S0968-0004(03)00087-2 Ohtsuka, 1996, Activation of brain B-Raf protein kinase by Rap1B small GTP-binding protein, J. Biol. Chem., 271, 1258, 10.1074/jbc.271.3.1258 Wang, 2006, Rap1-mediated activation of extracellular signal-regulated kinases by cyclic AMP is dependent on the mode of Rap1 activation, Molecular, 26, 2130 Minato, 2013, Rap G protein signal in normal and disordered lymphohematopoiesis, Exp. Cell Res., 319, 2323, 10.1016/j.yexcr.2013.04.009 Gyan, 2005, Mutation in RAP1 is a rare event in myelodysplastic syndromes, Leukemia, 19, 1678, 10.1038/sj.leu.2403882 Tsygankova, 2010, Downregulation of Rap1GAP in human tumor cells alters cell/matrix and cell/cell adhesion, Mol. Cell. Biol., 30, 3262, 10.1128/MCB.01345-09 Freeman, 2010, Preventing the activation or cycling of the Rap1 GTPase alters adhesion and cytoskeletal dynamics and blocks metastatic melanoma cell extravasation into the lungs, Cancer Res., 70, 4590, 10.1158/0008-5472.CAN-09-3414 Bailey, 2009, Activation of Rap1 promotes prostate cancer metastasis, Cancer Res., 69, 4962, 10.1158/0008-5472.CAN-08-4269 McSherry, 2011, Breast cancer cell migration is regulated through junctional adhesion molecule-A-mediated activation of Rap1 GTPase, Breast Cancer Res., 13, R31, 10.1186/bcr2853 Zhang, 2006, Identification of a putative tumor suppressor gene Rap1GAP in pancreatic cancer, Cancer Res., 66, 898, 10.1158/0008-5472.CAN-05-3025 Zheng, 2009, Down-regulation of Rap1GAP via promoter hypermethylation promotes melanoma cell proliferation, survival, and migration, Cancer Res., 69, 449, 10.1158/0008-5472.CAN-08-2399 Mitra, 2003, Rap1A and rap1B ras-family proteins are prominently expressed in the nucleus of squamous carcinomas: nuclear translocation of GTP-bound active form, Oncogene, 22, 6243, 10.1038/sj.onc.1206534 Noda, 1993, Structures and functions of the K rev-1 transformation suppressor gene and its relatives, Biochim. Biophys. Acta, 1155, 97 Altschuler, 1993, Mutational analysis of the cAMP-dependent protein kinase-mediated phosphorylation site of Rap1b, J. Biol. Chem., 268, 7527, 10.1016/S0021-9258(18)53207-5 Wittchen, 2013, Rap1 GTPase activation and barrier enhancement in rpe inhibits choroidal neovascularization in vivo, PloS One, 8, e73070, 10.1371/journal.pone.0073070 Wittchen, 2011, Isoform-specific differences between Rap1A and Rap1B GTPases in the formation of endothelial cell junctions, Small GTPases, 2, 65, 10.4161/sgtp.2.2.15735 Price, 2004, Rap1 regulates E-cadherin-mediated cell-cell adhesion, J. Biol. Chem., 279, 35127, 10.1074/jbc.M404917200 Yang, 2015, Expression of RAP1B is associated with poor prognosis and promotes an aggressive phenotype in gastric cancer, Oncol. Rep., 34, 2385, 10.3892/or.2015.4234 Chrzanowska-Wodnicka, 2008, Defective angiogenesis, endothelial migration, proliferation, and MAPK signaling in Rap1b-deficient mice, Blood, 111, 2647, 10.1182/blood-2007-08-109710 Lin, 2015, Glucocorticoids mediate induction of microRNA-708 to suppress ovarian cancer metastasis through targeting Rap1B, Nat. Commun., 6, 5917, 10.1038/ncomms6917 Zhang, 2012, miR-518b is down-regulated, and involved in cell proliferation and invasion by targeting Rap1b in esophageal squamous cell carcinoma, FEBS Lett., 586, 3508, 10.1016/j.febslet.2012.08.007 Alemayehu, 2013, beta-Arrestin2 regulates lysophosphatidic acid-induced human breast tumor cell migration and invasion via Rap1 and IQGAP1, PloS One, 8, e56174, 10.1371/journal.pone.0056174 Goto, 2010, Rap1 stabilizes beta-catenin and enhances beta-catenin-dependent transcription and invasion in squamous cell carcinoma of the head and neck, Clin. Cancer Res., 16, 65, 10.1158/1078-0432.CCR-09-1122 York, 1998, Rap1 mediates sustained MAP kinase activation induced by nerve growth factor, Nature, 392, 622, 10.1038/33451 Li, 2016, Protein kinase a-independent Ras protein activation cooperates with Rap1 protein to mediate activation of the extracellular signal-regulated kinases (ERK) by cAMP, J. Biol. Chem., 291, 21584, 10.1074/jbc.M116.730978 Takahashi, 2017, Phosphorylation of Rap1 by cAMP-dependent protein kinase (PKA) creates a binding site for KSR to sustain ERK activation by cAMP, J. Biol. Chem., 292, 1449, 10.1074/jbc.M116.768986 Zeiller, 2012, Ras and Rap1 govern spatiotemporal dynamic of activated ERK in pituitary living cells, Cell Signal, 24, 2237, 10.1016/j.cellsig.2012.08.006 Mochizuki, 2001, Spatio-temporal images of growth-factor-induced activation of Ras and Rap1, Nature, 411, 1065, 10.1038/35082594 Murphy, 2006, MAPK signal specificity: the right place at the right time, Trends Biochem. Sci., 31, 268, 10.1016/j.tibs.2006.03.009 Li, 2011, Inhibitory effects of Rap1GAP overexpression on proliferation and migration of endothelial cells via ERK and Akt pathways, J. Huazhong Univ. Sci. Technol. Med. Sci., 31, 721, 10.1007/s11596-011-0667-x Yan, 2008, Rap1a is a key regulator of fibroblast growth factor 2-induced angiogenesis and together with Rap1b controls human endothelial cell functions, Mol. Cell. Biol., 28, 5803, 10.1128/MCB.00393-08 Gao, 2006, Ras-associated protein-1 regulates extracellular signal-regulated kinase activation and migration in melanoma cells: two processes important to melanoma tumorigenesis and metastasis, Cancer Res., 66, 7880, 10.1158/0008-5472.CAN-06-0254 Gray-Schopfer, 2005, The role of B-RAF in melanoma, Cancer Metastasis Rev., 24, 165, 10.1007/s10555-005-5865-1 Lu, 2016, Rap1A promotes ovarian cancer metastasis via activation of ERK/p38 and notch signaling, Cancer Med., 5, 3544, 10.1002/cam4.946 Jia, 2017, RAP1B, a DVL2 binding protein, activates Wnt/beta-catenin signaling in esophageal squamous cell carcinoma, Gene, 611, 15, 10.1016/j.gene.2017.01.021